We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Asthma Control and Clinical Practice in Hungary 2009

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00900861
First Posted: May 13, 2009
Last Update Posted: December 4, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
A prospective study led amongst pulmonologists. Patients asthma control level will be evaluated based on GINA guideline criteria. HRQoL measured by Visual analogue scale. Clinical practice: non controlled patients therapy assessed.

Condition
Asthma Control Level

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Asthma Control and Clinical Practice in Hungary 2009

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Asthma control level [ Time Frame: 3 times ]

Secondary Outcome Measures:
  • Visual Analogue Scale [ Time Frame: 3 times ]
  • Routine Therapeutical habits in control maintenance [ Time Frame: 3 times ]

Estimated Enrollment: 3000
Study Start Date: April 2009
Study Completion Date: November 2009
Groups/Cohorts
1
Asthmatic patients above 18 y, treated with ICS or bronchodilators

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pulmonology outpatient clinics
Criteria

Inclusion Criteria:

  • Asthma patients treated with ICS or bronchodilators

Exclusion Criteria:

  • COPD
  • pulmonary cancer
  • pulmonary tuberculosis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900861


  Show 75 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Zoltan Bartfai, MD PhD Semmelweis University Budapest Pulmonology Clinic
Study Chair: Lilla Szabo AstraZeneca Hungary
Study Director: Eva Gulyas AstraZeneca Hungary
  More Information

Responsible Party: MCMD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00900861     History of Changes
Other Study ID Numbers: NIS-RHU-DUM-2009/1
First Submitted: May 12, 2009
First Posted: May 13, 2009
Last Update Posted: December 4, 2009
Last Verified: December 2009

Keywords provided by AstraZeneca:
asthma control level
visual analogue scale

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases